Clinical Trial Update: Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial evaluating trastuzumab combined with dose-dense Abraxane in breast cancer has completed enrollment with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Emory University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-06-14